Latest Administration News

Lachlan Star Limited has reported promising extensions of shallow gold mineralisation at its Killaloe Project in Western Australia and completed maiden drilling at its North Cobar Copper-Gold Project in New South Wales, supported by government co-funding and heritage clearances.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent and is preparing for a key FDA submission, while appointing a new president to lead its US operations.

Freedom Care Group Holdings reports a modest cash increase to $0.5 million but continues to grapple with delayed payments from the NDIA, while exploring options to relist on the ASX.

Freedom Care Group Holdings has revealed ongoing financial distress with key subsidiaries entering liquidation and persistent delays in payments from the NDIA, leaving the company with a diminished cash reserve and a strategic focus on asset sales and cost reduction.

Freedom Care Group Holdings has placed its main operating entity into administration following a sharp decline in cash receipts linked to delayed payments from the NDIA and an ongoing audit. The company’s cash balance dropped significantly, prompting urgent restructuring efforts.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

MEC Resources has bolstered its stake in Advent Energy with a $1.55 million loan while navigating a pivotal Federal Court hearing on the PEP 11 Joint Venture. Meanwhile, progress on Clean Hydrogen Technology signals potential growth avenues.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Bannerman Energy reported a strong cash position of AUD 89.3 million at the end of December 2025, supported by significant equity financing and ongoing exploration investments. The company’s funding runway now extends to over nine quarters, providing a solid buffer for its uranium exploration activities.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

Diablo Resources reported a net cash outflow of A$456k for operating activities in the December 2025 quarter, offset partially by a A$2 million equity raise. Despite this, the company’s cash runway remains limited to about one quarter, prompting plans for further funding.